
Keywords: Curcumin; Pulmonary bioavailability; Sepsis-induced acute lung injury (ALI); PVP K30; polyvinyl pyrrolidone K30; PEG 400; polyethylene glycol 400; ALI; acute lung injury; DMSO; dimethylsulfoxide; PBS; phosphate buffer solution; BALF; bronchoalveolar lavag